JP Stock MarketDetailed Quotes

4502 Takeda Pharmaceutical

Watchlist
  • 4217.0
  • +27.0+0.64%
20min DelayNot Open Nov 19 15:30 JST
6.71TMarket Cap46.26P/E (Static)

Takeda Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Takeda Pharmaceutical Q2 2025 Earnings Date

Currency：JPYOct 31, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
1.08T
1.18T
+96.82B
Beat Est.
+3.46%
+12.75%
+8.97%
EPS
--
28.59
--
+286.34%
Analyst Rating
Buy

Nov 18, 2024

Takeda Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 1.056T--
--2025/Q3-- / 1.132T--
Oct 31, 20242025/Q21.176T / 1.079T--
Jul 31, 20242025/Q11.208T / 1.081T--
May 9, 20242024/Q41.051T / 899.902B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 1.056T--
--2025/Q3-- / 1.132T--
Oct 31, 20242025/Q21.176T / 1.079T--
Jul 31, 20242025/Q11.208T / 1.081T--
May 9, 20242024/Q41.051T / 899.902B--

Unlock Free Earnings Estimates

Takeda Pharmaceutical Earnings Reports

  • Takeda Pharmaceutical: Confirmatory letter.

    Oct 31 02:16 ET

  • Takeda Pharmaceutical: Interim report - 148th period (2024/04/01 - 2025/03/31)

    Oct 31 02:14 ET

  • Takeda Pharmaceutical: Notice Concerning Revisions to Full Year Consolidated Financial Results (IFRS)

    Oct 31 02:00 ET

  • Takeda Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [IFRS] (consolidated)

    Oct 31 02:00 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 18, 2024

    Buy

    • Strong Buy

      38.89%

    • Buy

      5.56%

    • Hold

      55.56%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    JP
    Overall
    Symbol
    Latest Price
    % Chg

    No Data